Response to Comments: MolDX: Pharmacogenomics Testing

This document is a Response to Comments related to the MolDX Pharmacogenomics Testing LCD (DL38294) and notes the public comment period (10/07/2019–11/21/2019). It also notifies that the next MolDX pharmacogenomics LCD (L38294) had a notice period starting 06/11/2020 and an effective date of 07/26/2020. No clinical coverage, limitation, or frequency criteria are included in the provided text; clinical criteria should be extracted from the referenced LCDs themselves.

"This document is a Response to Comments for MolDX: Pharmacogenomics Testing (LCD DL38294) summarizing public comment period and notice period."

Sign up to see full coverage criteria, indications, and limitations.